Management of recurrent disease after radical prostatectomy.
about
Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy.Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case ReportICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research.Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.A fully-automated one-pot synthesis of [18F]fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F]fluoromethyl tosylate.(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.[Imaging diagnostics of advanced prostate cancer].Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patientsIs the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
P2860
Q30911744-4B2D4AEF-2E36-469B-A67B-0CC42D15F134Q31145236-A8329E91-9C73-4FFD-965A-B6A297F80FF0Q34054729-BABD26FE-0512-4D21-97FD-9079E1314D4FQ35081520-0FAB54FD-4F1C-4190-A1DE-FF2313C29F15Q35772886-DD50407B-BE4C-4701-AD97-C45498B1C639Q37873396-D4B3DD70-F748-46B5-97AF-8EA082CA008BQ38004182-AFC47962-D2D2-4631-B283-09C0BDF66018Q38284699-3878E2B4-A187-4EE2-A93C-480484188937Q40034822-E6E4EC61-D16F-444D-B0B1-0E3162B64770Q40586543-3CE99403-601A-4F85-897D-2D5A7B9A0754Q41840589-E91764D6-8358-460B-A641-6FD00DD3F76EQ52985772-9D833C22-E760-4EE8-B9CB-BF9A84B969A6Q53031298-FE8ED957-3E28-4FB7-8F67-455F46B15C10Q53117553-8F87EB49-D6B4-40B1-B155-D05971C368D3Q53171288-1FD30E96-F6A0-479D-8BDB-94E4953C841EQ57780536-FC72CFD6-2206-45C5-96D9-EEFCB30F57ADQ57817247-3BF5B30A-7F2D-420B-BA88-D0F3308946BE
P2860
Management of recurrent disease after radical prostatectomy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Management of recurrent disease after radical prostatectomy.
@ast
Management of recurrent disease after radical prostatectomy.
@en
type
label
Management of recurrent disease after radical prostatectomy.
@ast
Management of recurrent disease after radical prostatectomy.
@en
prefLabel
Management of recurrent disease after radical prostatectomy.
@ast
Management of recurrent disease after radical prostatectomy.
@en
P2860
P356
P1476
Management of recurrent disease after radical prostatectomy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.PCAN.4500732
P577
2004-01-01T00:00:00Z
P5875
P6179
1019906677